APC-activated long noncoding RNA inhibits colorectal carcinoma pathogenesis through reduction of exosome production

Feng‐Wei Wang, Chenhui Cao, Kai Han, Zhao Yongxiang, Muyan Cai, Zhicheng Xiang, Jiaxing Zhang, Jie-Wei Chen, Liping Zhong, Yong Huang, Sufang Zhou, Xiaohan Jin, Xin‐Yuan Guan, Rui‐Hua Xu, Dan XieJournal of Clinical Investigation 2021 · DOI · OpenAlex

Abstract

This report details a critical correction to a study investigating the role of APC-activated long noncoding RNA (lncRNA-APC1) in colorectal carcinoma (CRC). The study demonstrates that lncRNA-APC1 acts as a tumor suppressor by inhibiting exosome production. Corrected data for Figure 11D confirms that silencing lncRNA-APC1 significantly promotes angiogenesis and cell migration, effects that are partially mediated through the p38 MAPK signaling pathway.

Introduction

Colorectal carcinoma (CRC) remains a major global health challenge, characterized by complex intercellular communication within the tumor microenvironment. Exosomes, small extracellular vesicles, play a pivotal role in this communication by transporting bioactive molecules that promote tumor progression. The APC gene is a well-known tumor suppressor frequently mutated in CRC. This study explores how APC regulates exosome-mediated pathogenesis through a specific downstream effector, lncRNA-APC1.

Experimental Approach

The researchers employed several biological assays to elucidate the function of lncRNA-APC1:

  • shRNA-mediated Silencing: Used to knock down lncRNA-APC1 expression (sh3 group).
  • Capillary Tube Formation Assay: Evaluated the angiogenic potential of cancer cell-derived signals by measuring the formation of tube-like structures in endothelial cells.
  • Transwell Migration Assay: Measured the invasive capacity of CRC cells by counting those that migrated through a porous membrane.
  • Pathway Inhibition: Utilized siRNA against p38 to determine if the observed effects were dependent on the p38 MAPK pathway.

Results

The corrected Figure 11D provides robust evidence for the suppressive role of lncRNA-APC1 in CRC progression.

Figure 11D: Corrected data showing the impact of lncRNA-APC1 silencing and p38 inhibition on angiogenesis and cell migration.

As shown in the figure, silencing lncRNA-APC1 (sh3 group) led to a dramatic increase in both capillary tube formation and cell migration compared to the negative control (NC). Specifically, the number of tubes increased from approximately 10 to 40, while the number of migrated cells jumped from roughly 230 to nearly 500. Crucially, the addition of a p38 inhibitor (si-p38) significantly attenuated these pro-tumorigenic effects, reducing tube formation to approximately 20 and migrated cell counts to roughly 330. These results are statistically significant, confirming that lncRNA-APC1 loss drives CRC pathogenesis via a p38-dependent mechanism.

Key Insights

  • The "Brake" Mechanism: lncRNA-APC1 serves as a critical downstream effector of the APC tumor suppressor. When APC is functional, it maintains high levels of lncRNA-APC1, which restricts exosome production.
  • Exosomes as Drivers: The loss of lncRNA-APC1 results in the production of highly "pro-tumor" exosomes that stimulate both blood vessel formation and cell invasiveness.
  • The p38 Connection: The partial reversal of the knockdown effects by p38 inhibition identifies the p38 MAPK pathway as the specific signaling engine that lncRNA-APC1 normally suppresses.

Conclusion

This study highlights lncRNA-APC1 as a vital tumor-suppressive component of the APC signaling axis in colorectal cancer. By regulating exosome production and downstream p38 signaling, lncRNA-APC1 prevents the creation of a pro-angiogenic and pro-migratory microenvironment. These insights suggest that targeting the lncRNA-APC1/exosome/p38 axis could offer new therapeutic avenues for CRC treatment.

Summary updated

Abstract

Following the publication of this article, the authors noted that the images presented for Figure 11D (shRNA-3 lncRNA-APC1 group) were identical to the images for Figure 7D (shRNA-3 lncRNA-APC1 exo group, capillary tube formation assay) and Supplemental Figure 8D (si-1 APC group, transwell assay), respectively.The authors have provided the correct version of Figure 11D based on the original data, and the point values in the graphs have been updated accordingly.That version is below.
BibTeX
@article{wang2021apc,
  author = {Feng‐Wei Wang and Chenhui Cao and Kai Han and Zhao Yongxiang and Muyan Cai and Zhicheng Xiang and Jiaxing Zhang and Jie-Wei Chen and Liping Zhong and Yong Huang and Sufang Zhou and Xiaohan Jin and Xin‐Yuan Guan and Rui‐Hua Xu and Dan Xie},
  title = {{APC-activated long noncoding RNA inhibits colorectal carcinoma pathogenesis through reduction of exosome production}},
  journal = {Journal of Clinical Investigation},
  year = {2021},
  doi = {10.1172/jci149666},
}
Figure